High levels of pipeline activity are being observed in Progressive Supranuclear Palsy treatment during 2019. Clinical development activities are being undertaken by more than 15 companies including AbbVie Inc, AC Immune, AlzProtect SAS, Aquinnah Pharmaceuticals, Asceneuron SA and others.
A Significant contribution to the Progressive Supranuclear Palsy pipeline is being observed from emerging companies opting for new approaches to clinical development strategy. The early stage and late-stage Progressive Supranuclear Palsy pipeline included 18 compounds, driven by increasing number of targeted therapies. Progress is being made in accelerating compounds into advanced stages. However, fluctuating trends are being observed in average duration across three phases.
Increased understanding of underlying causes of Progressive Supranuclear Palsy condition and increased access to investments is encouraging growth of Progressive Supranuclear Palsy drug pipeline. However, despite high levels of pipeline activity, increasing clinical trial costs and decreasing drug approval rates is requiring companies to focus more on understanding clinical development pipeline compounds.
The research study is structured to provide clear and actionable insights into Progressive Supranuclear Palsy drug pipeline for companies to optimize spending levels by understanding competition, their pipeline products and prospect of further advances over the next few years.
The report addresses the discovery, research and pre-clinical stage active Progressive Supranuclear Palsy therapeutic candidates. Further, drugs in clinical stage including phase 1, phase 2, phase 3 and pre-registration phases are also analyzed.
The current report examines the current Progressive Supranuclear Palsy pipeline along with current development status, regulatory progress, mechanism of action, route of administration, collaborating companies, sponsors, molecule type, and research/discovery details.
In addition to drug overview, recent developments, the report also provides mechanism of action, Pre-clinical trial details and Clinical trial details for each of the drug candidates of Progressive Supranuclear Palsy. Further, orphan drug status, fast track designation, grants awarded and other special status for Progressive Supranuclear Palsy pipeline compounds are also included. This study was produced independently by VPAResearch from our proprietary databases, primarily to assist users to develop in-depth understanding of 2019 Progressive Supranuclear Palsy pipeline and formulate effective research and development strategies.
Research Methodology Our integrated data reports are built through robust research methodology to ensure our users can build on the insights and data accuracy for their expansion plans. Both primary and secondary research methods are used with stringent quality checks at each stage to evaluate trends, analysis and forecasts.
Scope of the Research
Progressive Supranuclear Palsy Pipeline candidates- - Pre-clinical Phase: Discovery, research, pre-clinical - Early Phase: Phase 1 and Phase 2 Progressive Supranuclear Palsy drugs - Late phase: Phase 3 and in-approval Progressive Supranuclear Palsy drugs
Companies involved in the Pipeline- - Company overview - Snapshot - Progressive Supranuclear Palsy therapeutic treatment activities
Details for each Progressive Supranuclear Palsy drug candidate- - Snapshot - Drug Name - Alternative Names - Company - Originator - Phase - Molecule Type - Orphan Drug Status - Drug Overview - Mechanism of Action - Current Status - Trial Details
Other details - Pre-clinical trials for each drug candidate - Clinical trials for each drug candidate
Recent Progressive Supranuclear Palsy therapeutic candidates, clinical trials, investments, grants, partnerships, licenses, awards and other news
Our reports have been used by over 10K customers, including:
Fragile X Syndrome - Pipeline Review, H2 2020 Summary This latest Pharmaceutical and Healthcare disease pipeline guide Fragile X Syndrome - Pipeline Review, H2 2020, provides an overview of the Fragile X Syndrome (Genetic Disorders) pipeline landscape. Fragile X syndrome is a genetic condition...
Influenzavirus A Infections - Global Clinical Trials Review, H2, 2020 Summary clinical trial report, “Influenzavirus A Infections Global Clinical Trials Review, H2, 2020" provides an overview of Influenzavirus A Infections Clinical trials scenario.This report provides top line data relating to the...
Dysmenorrhea Disease - Global Clinical Trials Review, H2, 2020 Summary clinical trial report, “Dysmenorrhea Disease - Global Clinical Trials Review, H2, 2020" provides an overview of Dysmenorrhea Clinical trials scenario.This report provides top line data relating to the clinical trials on Dysmenorrhea. Report...
Hyperphosphatemia Disease - Global Clinical Trials Review, H2, 2020 Summary clinical trial report, “Hyperphosphatemia Disease - Global Clinical Trials Review, H2, 2020" provides an overview of Hyperphosphatemia Clinical trials scenario.This report provides top line data relating to the clinical trials...
Lennox-Gastaut Syndrome Global Clinical Trials Review, H2, 2020 Summary clinical trial report, “Lennox-Gastaut Syndrome Global Clinical Trials Review, H2, 2020" provides an overview of Lennox-Gastaut Syndrome Clinical trials scenario.This report provides top line data relating to the clinical trials...